Joanne Ewing

Birmingham, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 22 publications

An evaluation of a real-world, multi-disciplinary, treatment-free remission programme for patients with Chronic Myeloid Leukaemia.

An evaluation of a real-world, multi-disciplinary, treatment-free remission programme for patients with Chronic Myeloid Leukaemia.

Journal: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
Published: October 09, 2025

The lysine-specific demethylase 1 (LSD1) inhibitor bomedemstat in myelofibrosis: results from a phase 1/2 study.

The lysine-specific demethylase 1 (LSD1) inhibitor bomedemstat in myelofibrosis: results from a phase 1/2 study.

Journal: Blood advances
Published: August 19, 2025

The lysine-specific demethylase 1 (LSD1) inhibitor bomedemstat in myelofibrosis: results from a phase 1/2 study.

The lysine-specific demethylase 1 (LSD1) inhibitor bomedemstat in myelofibrosis: results from a phase 1/2 study.

Journal: Blood advances
Published: August 19, 2025

Genome-wide analysis defines genetic determinants of MPN subtypes and identifies a sex-specific association at CDH22/CD40.

Genome-wide analysis defines genetic determinants of MPN subtypes and identifies a sex-specific association at CDH22/CD40.

Journal: Blood
Published: January 17, 2025

Outcomes and characteristics of nonmelanoma skin cancers in patients with myeloproliferative neoplasms on ruxolitinib.

Outcomes and characteristics of nonmelanoma skin cancers in patients with myeloproliferative neoplasms on ruxolitinib.

Journal: Blood
Published: August 25, 2023

The management of myelofibrosis: A British Society for Haematology Guideline.

The management of myelofibrosis: A British Society for Haematology Guideline.

Journal: British journal of haematology
Published: August 15, 2023

Diagnosis and evaluation of prognosis of myelofibrosis: A British Society for Haematology Guideline.

Diagnosis and evaluation of prognosis of myelofibrosis: A British Society for Haematology Guideline.

Journal: British journal of haematology
Published: August 15, 2023

Ruxolitinib Versus Best Available Therapy for Polycythemia Vera Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial.

Ruxolitinib Versus Best Available Therapy for Polycythemia Vera Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: May 01, 2023

Tamoxifen for the treatment of myeloproliferative neoplasms: A Phase II clinical trial and exploratory analysis.

Tamoxifen for the treatment of myeloproliferative neoplasms: A Phase II clinical trial and exploratory analysis.

Journal: Nature communications
Published: March 13, 2023

A retrospective real-world study of the current treatment pathways for myelofibrosis in the United Kingdom: the REALISM UK study.

A retrospective real-world study of the current treatment pathways for myelofibrosis in the United Kingdom: the REALISM UK study.

Journal: Therapeutic advances in hematology
Published: October 27, 2021

A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia.

A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia.

Journal: Blood
Published: June 10, 2021

COVID-19-associated oxidative damage to red blood cells.

COVID-19-associated oxidative damage to red blood cells.

Journal: British journal of haematology
Published: January 11, 2021
Showing 1-12 of 22

Last Updated: 09/26/2026